Full notification file
General informationNotification NumberB/NL/12/002Member State to which the notification was sentNetherlandsDate of acknowledgement from the Member State Competent Authority06/02/2012Title of the ProjectOncolytic adenovirus therapy using a prostate-specific conditionally replication-competent adenovirus as an adjuvant treatment for localised prostate cancerProposed period of release:01/11/2012 to 01/11/2022Name of the Institute(s) or Company(ies)3. Is the same GMO release planned elsewhere in the Community?NoHas the same GMO been notified elsewhere by the same notifier?NoGMO characterizationGMO is a:DNA VirusIdentity of the GMO:Genus Mastadenovirus, species human Adenovirus subgenus C, serotype 5.Information relating to the recipient or parental organisms from wich the GMO is derived| Common Name | Genus | Species | Subspecies | Strain | Pathovar | | Human adenovirus type 5 | Mastadenovirus | human adenovirus | subgenus C | human serotype 5 | - |
|
European Commission administrative informationConsent given by the Member State Competent Authority:Not known